Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Lung Neoplasms 4Colorectal Neoplasms 3Neoplasm Metastasis 2Carcinoma, Renal Cell 2Solid Tumors 1Rectal Neoplasms 1Neoplasms 1Kidney Neoplasms 1Colonic Neoplasms 1Brain Neoplasms 1Advanced Solid Tumor 1

Interventions

Specimen Handling 43pembrolizumab 42Biopsy 36Magnetic Resonance Spectroscopy 34Paclitaxel 21Carboplatin 21Gemcitabine 20Nivolumab 19Irinotecan 17Radiosurgery 15Cisplatin 13Taxes 11Pemetrexed 11Ipilimumab 11Fluorouracil 11Cetuximab 11trastuzumab deruxtecan 10olaparib 10Leucovorin 10130-nm albumin-bound paclitaxel 10abemaciclib 9Oxaliplatin 9Cyclophosphamide 9Capecitabine 9Bevacizumab 9palbociclib 8durvalumab 8Fulvestrant 8X-Rays 7Trastuzumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × adagrasib × 90 days × Clear all
NCT03994796 2026-04-13

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Alliance for Clinical Trials in Oncology

Phase 2 Active not recruiting
50 enrolled
CNS

Brain Neoplasms, Neoplasm Metastasis

NCT05853575 2026-03-27

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

Mirati Therapeutics Inc.

Phase 2 Active not recruiting
200 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡